Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Shield Therapeutics Plc | LSE:STX | London | Ordinary Share | GB00BYV81293 | ORD 1.5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.10 | -3.39% | 2.85 | 2.80 | 2.90 | 2.95 | 2.85 | 2.90 | 2,684,036 | 08:23:30 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 13.09M | -33.29M | -0.0429 | -0.66 | 22.88M |
| Date | Subject | Author | Discuss |
|---|---|---|---|
| 31/10/2024 17:47 | Has anyone asked why they directors have not bought the shares yet ?? | krp10 | |
| 31/10/2024 17:31 | So you believe people are investing in Stx based on what PATT posts on here? Hahaha deluded | zeus19 | |
| 31/10/2024 14:45 | SP has reacted well | r9505571 | |
| 31/10/2024 14:44 | Key take offs for me…… NSP to be $190+ Q4 Anticipated 20% growth Q4 AOP equity seems fixed at 4p | purchaseatthetop | |
| 31/10/2024 14:40 | So you believe people are investing in Stx based on what PATT posts on here? Hahaha deluded | zeus19 | |
| 31/10/2024 14:38 | I have lost concentration.The July 4th sales debacle has lost me. Questioned on cost reductions when inflation is high. Thinking about patient ambassadors for digital channels. Why are sales in the EU NOT showing growth? To do with the numbers of countries Norgine is present in. Comparable pricing in Europe is lower? No Reference pricing in US. Are you targeting high GDP countries? Shield is happy to go anywhere. Middle East, Africa India etcDo you expect forward buying before Christmas? Patients will hit their out of pocket in Q4. Should reset in Q1. Should continue to see quarterly growth | r9505571 | |
| 31/10/2024 14:26 | Not a months supply but 28 days. Edit :- So if on it for life it will be 13 prescriptions per year rather than 12. | bunlop | |
| 31/10/2024 14:23 | Peak revenue forecasted to be $450m. Filed for approval in Korea. Approval 2025. China phase III study. Approval 2026.Walkthrough of Q3 results. Goal to be cash flow positive by end of 2025.Net price per script hoping to be maintained of bettered in Q4. Cost reduction. Expansion of working capital from $10 to $15m. $10m of new equity financing from AOP. AOP will hold >50% of the issued capital. Shield will continue to report on quarterly sales figures. Trying to get into European markets. Decision lies with Norgine. 70% of sales are continuing subscribers. Word of mouth is spreading among HCP.$192 per prescription is per patient per month in the US | r9505571 | |
| 31/10/2024 14:22 | So you believe people are investing in Stx based on what PATT posts on here? Hahaha deluded | zeus19 | |
| 31/10/2024 14:03 | I'm in the presentation. Will try and post a summary here | r9505571 | |
| 31/10/2024 14:02 | And just as the investor meets starts we finally go blue. | purchaseatthetop | |
| 31/10/2024 11:54 | Certainly. But when they get to $100m revenues Viatris start paying $5m lumps up to $30m. That covers the debt! | purchaseatthetop | |
| 31/10/2024 11:46 | Whatever. 45 percent of total funds their operations and management of debt | skcots48 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
